Celcuity Inc. is a cellular analysis company. It engaged in discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The company's proprietary CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular activity driving a patient's cancer and the targeted therapy. Celcuity Inc. is based in Minneapolis, United States.
Revenue (Most Recent Fiscal Year) | -- |
Net Income (Most Recent Fiscal Year) | $-111.78M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | -- |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.17 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -- |
Net Margin (Trailing 12 Months) | -- |
Return on Equity (Trailing 12 Months) | -96.21% |
Return on Assets (Trailing 12 Months) | -49.44% |
Current Ratio (Most Recent Fiscal Quarter) | 6.61 |
Quick Ratio (Most Recent Fiscal Quarter) | 6.61 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 1.14 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $3.11 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.86 |
Earnings per Share (Most Recent Fiscal Year) | $-2.83 |
Diluted Earnings per Share (Trailing 12 Months) | $-3.03 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 37.87M |
Free Float | 31.89M |
Market Capitalization | $448.72M |
Average Volume (Last 20 Days) | 0.14M |
Beta (Past 60 Months) | 0.37 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 15.77% |
Percentage Held By Institutions (Latest 13F Reports) | 63.33% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |